Generation Bio Co. (GBIO) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.53 per share a year ago. These figures ...

Toronto, Ontario--(Newsfile Corp. - March 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company”), a clinical stage pharmaceutical company dedicated to the ...

Following a pre-specified interim analysis, the Data Safety Monitoring Board (DSMB) recommended the DRAGON trial, a pivotal Phase 3 trial in ...

16:03 EDT Gossamer Bio (GOSS) reports Q4 revenue $9.4M, consensus $7.0M Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses.

The company expects its annual revenue to be between $1.01 billion and $1.012 billion, compared with analysts' average estimate of $1.03 billion, according to data compiled by LSEG. It forecast ...

Q4 Quarterly Services Report: U.S. selected services total revenue rose 1.1% Q/Q to $5,780.7B (revised from the advance estimate of $5,781.6B), the U.S. Census Bureau said on Thursday. The ...

The company reported fourth-quarter sales growth of 4.5% year-on ... and operating income for the quarter declined 49.2% to $294.2 million. EPS of $0.87 missed the consensus estimate of $1.51.

ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — Regenxbio Inc. (RGNX) on Thursday reported a loss of $51.2 million in its fourth quarter. On a per-share basis, the Rockville, Maryland-based company said ...

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through ...

The report revealed higher-than-expected diluted earnings per share-- $6.56, compared to the $6.29 estimate ... income is expected to land in the $257 million to $309 million range for the year.